People: ACADIA Pharmaceuticals Inc (ACAD.W)

Summary

Name	Age	Since	Current Position
Leslie Iversen	75	2000	Independent Chairman of the Board
Uli Hacksell	62	2009	President, Chief Executive Officer, Director
Thomas Aasen	52	2009	Chief Financial Officer, Executive Vice President, Treasurer, Chief Business Officer
Roger Mills	55	2006	Executive Vice President - Development
Glenn Baity	43	2004	Vice President, General Counsel, Secretary
Stephen Biggar	42	2013	Director
Michael Borer	54	2005	Independent Director
Laura Brege	55	2008	Independent Director
Mary Gray	60	2005	Independent Director
Lester Kaplan	62	1997	Independent Director
Torsten Rasmussen	68	1998	Independent Director
William Wells	52	2012	Independent Director

» Insider Trading

Biographies

Name	Description
Leslie Iversen	Dr. Leslie L. Iversen, Ph.D., is Independent Chairman of the Board of ACADIA Pharmaceuticals, Inc. He has served as a director since 1998. He also was a founding member of Scientific Advisory Board. Dr. Iversen is currently a Visiting Professor of Pharmacology at University of Oxford, England, where he has taught since 1995. He was previously a Professor of Pharmacology at King’s College, London where he was Director of the Wolfson Centre for Age Related Diseases from 1999 until 2004. Dr. Iversen is internationally recognized for his fundamental contributions to the understanding of neurotransmission. Dr. Iversen served as Vice President of Neuroscience Research, Merck Research Laboratories and Director of the Neuroscience Research Center of Merck Research Laboratories in the UK. He was formerly Director of the Medical Research Council Neurochemical Pharmacology Unit in Cambridge. Dr. Iversen received a Ph.D. and B.A. from the University of Cambridge.
Uli Hacksell	Dr. Uli Hacksell Ph.D., is President, Chief Executive Officer, Director of ACADIA Phamaceuticals Inc. From February 1999 to September 2000, he served as Executive Vice President of Drug Discovery. From August 1991 to February 1999, Dr. Hacksell held various senior executive positions at Astra, a pharmaceutical company, including Vice President of Drug Discovery and Technology as well as President of Astra Draco, development subsidiaries, where he directed an organization of more than 1,100 employees. From August 1991 to May 1994, he served as Vice President of CNS Preclinical R&D at Astra Arcus, another subsidiary. Earlier in his career, Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University in Sweden and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. He currently serves on the board of directors of SLS Invest AB. Dr. Hacksell received a Master of Pharmacy and a Ph.D. in Medicinal Chemistry from Uppsala University.
Thomas Aasen	Mr. Thomas H. Aasen is Chief Financial Officer, Chief Business Officer, Executive Vice President, Treasurer of ACADIA Pharmaceuticals, Inc. Prior to joining, Mr. Aasen held financial management positions at several publically traded life sciences companies, including Axys Pharmaceuticals, formerly called Sequana Therapeutics, Genta, Inc., and Gen-Probe, Inc. Earlier in his career, Mr. Aasen held various positions in public accounting at KPMG Peat Marwick, including Audit Manager. He has 30 years of professional finance and accounting experience focused primarily on the life sciences industry. Mr. Aasen received a B.S. degree with honors from San Diego State University and is a licensed certified public accountant (inactive status) in the State of California.
Roger Mills	Dr. Roger M. Mills, M.D., is Executive Vice President - Development, Chief Medical Officer of ACADIA Pharmaceuticals, Inc. Prior to joining, Dr. Mills held the position of Vice President, Development at Pfizer Global R&D, a division of Pfizer Inc., which is a global pharmaceutical company, for a five-year period. In this capacity, he was responsible for the management and direction of drug development activities at the Pfizer campus in La Jolla, California, and played a key role in the development of Sutent®, a new multikinase inhibitor for patients with advanced renal cell carcinoma and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Mills held senior clinical management positions at Gilead Sciences, where he served as project leader in the development of Tamiflu®, treatment for influenza, and at Abbott Laboratories, where he played an important role in the development of antiviral drugs. Earlier in his career, he held several senior positions at the Wellcome Foundation, including Scientific Advisor for Group Marketing and Therapeutic Area Head, Cardiovascular Marketing. Dr. Mills received his medical degree at the Charing Cross Hospital Medical School in London and his specialized medical training at the Royal College of General Practitioners in London.
Glenn Baity	Mr. Glenn F. Baity is Vice President, General Counsel, Secretary of ACADIA Pharmaceuticals Inc. From February 2000 until joining, Mr. Baity was a senior associate at Cooley LLP in their San Diego office, working with a variety of public and private companies on transactional matters, including M&A, financings, compensation and equity matters, and corporate governance. From January 1997 to January 2000, Mr. Baity was an associate in the San Francisco office of Brown & Wood LLP (now Sidley Austin LLP) working primarily on public financings for established companies while representing bulge bracket underwriters, such as Goldman Sachs, Merrill Lynch and Morgan Stanley. Mr. Baity received a J.D. degree from the University of California, Los Angeles and received a B.A. from the University of California, Berkeley.
Stephen Biggar	Dr. Stephen R. Biggar, M.D., Ph.D., is Independent Director of Acadia Pharmaceuticals Inc. Dr. Biggar serves as a Partner at Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. From April 2002 to October 2006, he served as a Principal with Baker Brothers Investments which he had joined as an Associate in April 2000. Dr. Biggar also serves as a director for Synageva BioPharma Corp., a publicly traded biotechnology company. Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester.
Michael Borer	Mr. Michael T. Borer is Independent Director of ACADIA Pharmaceuticals, Inc. Mr. Borer served as Chief Executive Officer and President of Xcel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system, until the sale of the company to Valeant Pharmaceuticals International in early 2005. Prior to founding Xcel in early 2001, Mr. Borer served as Senior Vice President and Chief Financial Officer of Dura Pharmaceuticals, Inc. and held other management positions there from 1994 through 2000. Prior to Dura, Mr. Borer spent 12 years in public accounting with Deloitte & Touche in its audit services group. He holds a bachelor’s degree in accounting from San Diego State University.
Laura Brege	Ms. Laura A. Brege is Independent Director of ACADIA Pharmaceuticals, Inc. Currently, Ms. Brege is Chief Executive Officer and President of Nodality, Inc., a private company focused on innovative personalized medicine. Prior to joining Nodality in September 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., from June 2006 to December 2011, including Executive Vice President and Chief Operating Officer. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies, since 1999. Prior to Red Rock, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege currently sits on the board of Pacira Pharmaceuticals, Inc., a public company. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. Ms. Brege also serves on the board of The Ohio University Foundation. During the past five years, Ms. Brege also served on the board of Angiotech Pharmaceuticals, Inc., a public company.
Mary Gray	Dr. Mary Ann Gray, Ph.D., is Independent Director of ACADIA Pharmaceuticals, Inc. Currently, Dr. Gray is President of Gray Strategic Advisors, LLC, a company which she started in 2003 and which provides strategic consulting services to the biotechnology industry. Dr. Gray also serves on the boards of directors of Dyax Corp. and Senomyx, Inc., each of which is a publicly-traded company. During the past five years, Dr. Gray also served on the board of directors for each of GTC Biotherapeutics Inc. and Telik, Inc., each a public company, as well as Apthera Inc., a privately held company. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read and Kidder Peabody for an aggregate of nine years. Dr. Gray holds a Ph.D. degree in pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer.
Lester Kaplan	Dr. Lester J. Kaplan, Ph.D., is Independent Director of ACADIA Pharmaceuticals, Inc. Dr. Kaplan was Executive Vice President and President, Research and Development, at Allergan, Inc. from November 2003 to April 2004. Dr. Kaplan joined Allergan in 1983 and, prior to being appointed to Executive Vice President, was Corporate Vice President, Research and Development and Global BOTOX from June 1998 to November 2003. Dr. Kaplan was elected to Allergan’s board of directors in 1994 and served in that capacity until April 2004. Dr. Kaplan is Executive Chairman of the Board of Aciex Therapeutics Inc., Chairman of the Board of Altheos, Inc., and a member of the board of The National Neurovision Research Institute. He serves on the Scientific Advisory Board of Bay City Capital. In particular, as the Company pursues its Phase III program for its lead compound, Dr. Kaplan’s prior experience with clinical trials and other development activities provide invaluable insight for the Board. Dr. Kaplan received a M.S. and Ph.D. in organic chemistry from the University of California, Los Angeles.
Torsten Rasmussen	Mr. Torsten Erik Rasmussen is Independent Director of ACADIA Pharmaceuticals, Inc. Mr. Rasmussen has been President and Chief Executive Officer of Morgan Management ApS, a management advisory and consulting company, since 1997. Prior to founding Morgan Management in 1997, Mr. Rasmussen had held the position of Executive Vice President, Operations at the LEGO Group (LEGO A/S) in Denmark since 1981. He currently serves as a deputy chairman of the board of TK Development A/S, a Danish company which is quoted on the Danish Stock Exchange. He also sits on the board of a number of privately held Danish companies. He previously served as a board member in the capacity of chairman, deputy chairman or ordinary board member of a number of Danish companies of which the following are quoted on the Danish Stock Exchange: Bang & Olufsen A/S (1994-2007), Coloplast A/S (1992-2010), Vestas Wind Systems A/S (1998-2012), and A/S Det Oestasiatiske Kompagni (1998-2010). Mr. Rasmussen holds an M.B.A. from IMD in Lausanne, Switzerland.
William Wells	Mr. William M. Wells is Independent Director of ACADIA Pharmaceuticals Inc. Mr. Wells was Chief Executive Officer of Biovail Corporation from May 2008 through the time of its merger with Valeant Pharmaceuticals International, Inc. in September 2010, during which time he led Biovail’s strategic transformation into a specialty pharmaceutical company focused on specialty central nervous system markets. Following the merger, Mr. Wells served as Chairman of Valeant until December 2010. He was originally elected to the board of directors of Biovail in June 2005 and later served as Lead Director until his appointment as Chief Executive Officer. Prior to joining Biovail, Mr. Wells held a number of senior executive positions, including Chief Financial Officer of Loblaw Companies Limited, food distributor and provider of general merchandise products, drugstore and financial products and services, Chief Financial Officer of Bunge Limited, a U.S. headquartered company engaged in the global agribusiness, fertilizer and food product industries, and financial management positions at McDonald’s Corporation in the U.S. and Brazil. Mr. Wells is currently Chairman of the Board of Evizone Ltd., a privately held online communications service firm, and is a member of the Board of Directors of Myriant Corporation and EnerCare Inc. Mr. Wells holds a Master’s degree in International Business from the University of South Carolina and a Bachelor’s degree in Philosophy and English from the University of Western Ontario.

Basic Compensation

Name	Fiscal Year Total
Leslie Iversen	--
Uli Hacksell	933,353
Thomas Aasen	572,944
Roger Mills	619,762
Glenn Baity	478,082
Stephen Biggar	--
Michael Borer	--
Laura Brege	--
Mary Gray	--
Lester Kaplan	--
Torsten Rasmussen	--
William Wells	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Leslie Iversen	0	0
Uli Hacksell	424,084	3,093,980
Thomas Aasen	199,000	1,533,340
Roger Mills	0	0
Glenn Baity	0	0
Stephen Biggar	0	0
Michael Borer	0	0
Laura Brege	0	0
Mary Gray	0	0
Lester Kaplan	0	0
Torsten Rasmussen	0	0
William Wells	0	0

Insider Trading

Name	Shares Traded	Price
HACKSELL ULI	20,449	$12.34
HACKSELL ULI	20,449	$0.00
HACKSELL ULI	20,449	$0.00
HACKSELL ULI	20,449	$1.08
HACKSELL ULI	19,551	$0.00
HACKSELL ULI	19,551	$0.00
HACKSELL ULI	19,551	$12.71
HACKSELL ULI	19,551	$1.08
BAITY GLENN F	10,000	$13.15
BAITY GLENN F	10,000	$1.62
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	10,000	$12.26
HACKSELL ULI	16,729	$12.32
BAITY GLENN F	10,000	$1.55
HACKSELL ULI	16,729	$0.00
HACKSELL ULI	16,729	$1.08
BAITY GLENN F	20,000	$12.30
HACKSELL ULI	16,729	$0.00
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	20,000	$12.50
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	10,000	$13.00
BAITY GLENN F	20,000	$12.74
BAITY GLENN F	10,000	$1.55

» Full list on Insider Trading

People: ACADIA Pharmaceuticals Inc (ACAD.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: